Clinical Trials

The clinical trials listed below are for informational purposes only and are not endorsed by the AST. More information on clinical trials can be found in our clinical trials brochure. For information about posting a clinical trial, contact JoAnn Gwynn at jgwynn@myast.org.

Clinical Trials for Kidney Recipients

• Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as Adjunctive Treatment For Refractory Antibody-Mediated Rejection (ARMOR) in Adult Renal Transplant Recipients
  Sponsor: CSL Behring
  Organ Type: Kidney
  Ages Accepted: 18+
  Genders Accepted: Both male and female 
  Expected Study Completion Date: Thursday, January 15, 2026 
   
• A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants
  Sponsor: Medeor Therapeutics, Inc.
  Organ Type: Kidney
  Ages Accepted: Age ≥18 and ≤70 years
  Genders Accepted: Both male and female
  Expected Study Completion Date: January, 2022
   

Clinical Trials for Other Organ Types

• Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
  Sponsor: Atara Biotherapeutics
  Organ Type: All organs
  Ages Accepted: All ages
  Genders Accepted: Both male and female
  Expected Study Completion Date: Monday, November 30, 2020
  Other Requirements
   
• A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant (RR) to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
  Sponsor: Takeda Pharmaceutical Company Limited
  Organ Type: Hematopoietic Stem Cell Transplant, All organs
  Ages Accepted: ≥12 years of age
  Genders Accepted: Both male and female
  Expected Study Completion Date: Tuesday, September 29, 2020
  Other Requirements
   
• A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Recipients
  Sponsor: Takeda Pharmaceutical Company Limited
  Organ Type: Hematopoietic Stem Cell Transplant
  Ages Accepted: ≥16 years of age
  Genders Accepted: Both male and female
  Expected Study Completion Date: Tuesday, August 13, 2021
  Other Requirements